Cargando…

TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer

BACKGROUND: Drug resistance and recurrence are main contributors to the poor prognosis of ovarian cancer. Cisplatin is a platinum compound which is widely used in the treatment of various solid tumors including ovarian cancer. Up to now, the mechanism of cisplatin resistance in ovarian cancer is unc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yixuan, Zhu, Keyu, Guan, Xiaolin, Xie, Suhong, Wang, Yanchun, Tong, Ying, Guo, Lin, Zheng, Hui, Lu, Renquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487155/ https://www.ncbi.nlm.nih.gov/pubmed/34598710 http://dx.doi.org/10.1186/s13048-021-00884-z

Ejemplares similares

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
por: Guan, Xiaolin, et al.
Publicado: (2022)

IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis
por: Zheng, Hui, et al.
Publicado: (2023)

VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1α/HO-1 pathway
por: Tong, Ying, et al.
Publicado: (2021)

CALD1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers
por: Liu, Yixuan, et al.
Publicado: (2021)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
por: Zhang, Jing, et al.
Publicado: (2021)

TPX2 promotes ovarian tumorigenesis by interacting with Lamin A/C and affecting its stability
por: Meng, Xin, et al.
Publicado: (2023)

Therapeutic targeting of the TPX2/TTK network in colorectal cancer
por: Shaath, Hibah, et al.
Publicado: (2023)

Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients
por: Zheng, Hui, et al.
Publicado: (2020)

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

Differentially Expressed Genes in Clear Cell Renal Cell Carcinoma as a Potential Marker for Prognostic and Immune Signatures
por: Tong, Ying, et al.
Publicado: (2021)

A Risk of Venous Thromboembolism Algorithm as a Predictor of Venous Thromboembolism in Patients with Colorectal Cancer
por: Chen, Ying, et al.
Publicado: (2021)

TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer
por: Maire, Virginie, et al.
Publicado: (2013)

Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma
por: Wang, Jia, et al.
Publicado: (2017)

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
por: Deng, Minjie, et al.
Publicado: (2019)

GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer
por: Huang, Yan, et al.
Publicado: (2021)

Molecular basis underlying resistance to Mps1/TTK inhibitors
por: Koch, A, et al.
Publicado: (2016)

Expression and Function Analysis of Mitotic Checkpoint Genes Identifies TTK as a Potential Therapeutic Target for Human Hepatocellular Carcinoma
por: Liang, Xiao-Dong, et al.
Publicado: (2014)

Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer
por: Miao, Ruoyu, et al.
Publicado: (2016)

Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer
por: Zheng, Hui, et al.
Publicado: (2015)

Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
por: Yan, Tianqing, et al.
Publicado: (2022)

In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1
por: Khedkar, Harshita Nivrutti, et al.
Publicado: (2021)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
por: Yu, Jian, et al.
Publicado: (2022)

MUS81 Participates in the Progression of Serous Ovarian Cancer Associated With Dysfunctional DNA Repair System
por: Lu, Renquan, et al.
Publicado: (2019)

TTK is a favorable prognostic biomarker for triple-negative breast cancer survival
por: Xu, Qianqian, et al.
Publicado: (2016)

TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells
por: Liu, Xing, et al.
Publicado: (2015)

Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
por: Guo, Ying, et al.
Publicado: (2022)

Evaluation of TTK Chitra heart valve prosthesis in pediatric patients
por: Varma, Praveen Kerala, et al.
Publicado: (2022)

Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma
por: Wang, Yanchun, et al.
Publicado: (2018)

MiR-582-5p Inhibits Bladder Cancer-Genesis by Suppressing TTK Expression
por: Tian, Yudong, et al.
Publicado: (2020)

Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors
por: De Giorgi, Ugo, et al.
Publicado: (2019)

Scaffold-Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitors
por: Langdon, Sarah R., et al.
Publicado: (2013)

Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis
por: Pachis, Spyridon T., et al.
Publicado: (2018)

CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma
por: Chan, Cerise Yuen-Ki, et al.
Publicado: (2022)

Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer
por: Lu, Renquan, et al.
Publicado: (2011)

Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression
por: Zheng, Hui, et al.
Publicado: (2019)

Establishment of a detection assay for DNA endonuclease activity and its application in the screening and prognosis of malignant lymphoma
por: Lu, Renquan, et al.
Publicado: (2018)

A novel role for TTK in homologous recombination: implications for breast cancer radiosensitivity
por: Chandler, Benjamin C., et al.
Publicado: (2020)

TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer
por: Yang, Qiannan, et al.
Publicado: (2020)

TTK (threonine tyrosine kinase) regulates the malignant behaviors of cancer cells and is regulated by microRNA-582-5p in ovarian cancer
por: Lu, Na, et al.
Publicado: (2021)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ulo12ci93fcd0m4l3n16mb6b6e